Inspire Investing LLC Purchases Shares of 5,547 Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Inspire Investing LLC purchased 5,547 shares of Jazz Pharmaceuticals, valued at approximately $689,000, in the first quarter of the year.
• Recently, Jazz Pharmaceuticals reported an EPS of -$8.25 for the quarter, missing estimates, while revenues increased by 2.1% year-over-year.
• Analysts are generally optimistic about Jazz Pharmaceuticals, with fourteen giving it a buy rating and an average price target of $178.67.

Inspire Investing LLC purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 5,547 shares of the specialty pharmaceutical company's stock, valued at approximately $689,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in JAZZ. Focus Partners Wealth acquired a new stake in Jazz Pharmaceuticals during the fourth quarter valued at $551,000. CX Institutional acquired a new stake in Jazz Pharmaceuticals during the first quarter valued at $4,316,000. Envestnet Portfolio Solutions Inc. grew its position in Jazz Pharmaceuticals by 38.9% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 4,369 shares of the specialty pharmaceutical company's stock valued at $542,000 after buying an additional 1,223 shares during the period. GAMMA Investing LLC grew its position in Jazz Pharmaceuticals by 63.7% during the first quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company's stock valued at $126,000 after buying an additional 395 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new stake in Jazz Pharmaceuticals during the first quarter valued at $1,888,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Down 1.8%

NASDAQ JAZZ opened at $126.16 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The stock has a market capitalization of $7.65 billion, a PE ratio of -18.75, a price-to-earnings-growth ratio of 7.97 and a beta of 0.24. The firm has a 50 day moving average of $118.59 and a two-hundred day moving average of $116.54.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company's revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the firm earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Analysts Set New Price Targets

JAZZ has been the topic of several recent analyst reports. Zacks Research raised shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Truist Financial increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a report on Thursday, August 28th. Royal Bank Of Canada raised their price target on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a research note on Thursday, August 28th. The Goldman Sachs Group raised their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a research note on Friday, August 29th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $178.67.

Insider Buying and Selling

In related news, Director Bruce C. Cozadd sold 6,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the sale, the director owned 429,973 shares in the company, valued at $55,303,127.26. This represents a 1.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.